SK14102003A3 - Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv - Google Patents

Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv Download PDF

Info

Publication number
SK14102003A3
SK14102003A3 SK1410-2003A SK14102003A SK14102003A3 SK 14102003 A3 SK14102003 A3 SK 14102003A3 SK 14102003 A SK14102003 A SK 14102003A SK 14102003 A3 SK14102003 A3 SK 14102003A3
Authority
SK
Slovakia
Prior art keywords
igs5
nep
seq
combined
disease
Prior art date
Application number
SK1410-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Claudia Berger
Yvan Fischer
Dagmar H�Ltje
Harald Waldeck
Michael Weske
Dieter Ziegler
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Publication of SK14102003A3 publication Critical patent/SK14102003A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
SK1410-2003A 2001-05-18 2002-05-14 Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv SK14102003A3 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112231 2001-05-18
US29233701P 2001-05-22 2001-05-22
PCT/EP2002/005259 WO2002094176A2 (en) 2001-05-18 2002-05-14 Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments

Publications (1)

Publication Number Publication Date
SK14102003A3 true SK14102003A3 (sk) 2004-08-03

Family

ID=32842671

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1410-2003A SK14102003A3 (sk) 2001-05-18 2002-05-14 Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv

Country Status (15)

Country Link
US (1) US20040162345A1 (zh)
EP (1) EP1397141A2 (zh)
JP (1) JP2004536063A (zh)
CN (1) CN1520299A (zh)
AR (1) AR039352A1 (zh)
BR (1) BR0209855A (zh)
CA (1) CA2447598A1 (zh)
CZ (1) CZ20033183A3 (zh)
HU (1) HUP0400988A3 (zh)
MX (1) MXPA03010341A (zh)
PL (1) PL367093A1 (zh)
RU (1) RU2003136077A (zh)
SK (1) SK14102003A3 (zh)
WO (1) WO2002094176A2 (zh)
ZA (1) ZA200308098B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784327B2 (en) 1999-11-19 2006-03-09 Abbvie B.V. Human enzymes of the metalloprotease family
WO2004010106A2 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
WO2005067937A1 (en) * 2004-01-12 2005-07-28 Solvay Pharmaceuticals B.V. Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders
US7232813B2 (en) 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
EP1753432A1 (en) * 2004-05-14 2007-02-21 Solvay Pharmaceuticals GmbH Medicaments containing dually acting inhibitors of neutral endopeptidase and of human soluble endopeptidase for the treatment of sexual dysfunction
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
EP1776095A1 (en) * 2004-06-23 2007-04-25 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
US7816347B2 (en) 2004-12-15 2010-10-19 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
BRPI0608184A2 (pt) * 2005-02-18 2009-11-17 Solvay Pharm Gmbh composições farmacêuticas compreendendo inibidores da nep, inibidores da nep, inibidores do sistema de produção de endotelina endógena e diuréticos
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
KR101970505B1 (ko) * 2012-12-26 2019-04-19 (주)아모레퍼시픽 멜라닌 형성 억제제를 함유하는 미백용 피부 외용제 조성물
MD3259253T2 (ro) 2015-02-16 2020-06-30 Univ Queensland Sulfoniluree și compuși înrudiți și utilizări ale acestora
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
TWI789401B (zh) 2017-07-07 2023-01-11 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
RU2020110366A (ru) * 2017-08-15 2021-09-16 Инфлазоум Лимитед Новые соединения сульфонамидкарбоксамидов
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
CA2096418C (en) * 1990-11-26 2001-11-20 Philip J. Barr Expression of pace in host cells and methods of use thereof
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US20020086405A1 (en) * 2000-09-25 2002-07-04 Inmaculada Silos-Santiago 56638, a novel human neprilysin protease and uses thereof
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
JP2001275687A (ja) * 2000-04-04 2001-10-09 Masafumi Matsuo 膜結合型メタロプロテアーゼ及びその可溶性分泌型
US6991916B2 (en) * 2000-07-14 2006-01-31 Pfizer Inc. Compounds for the treatment of sexual dysfunction
GB0017387D0 (en) * 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20030119714A1 (en) * 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
EP1397141A2 (en) 2004-03-17
MXPA03010341A (es) 2004-03-10
ZA200308098B (en) 2004-10-18
US20040162345A1 (en) 2004-08-19
AR039352A1 (es) 2005-02-16
RU2003136077A (ru) 2005-08-10
HUP0400988A2 (hu) 2004-08-30
CZ20033183A3 (cs) 2004-07-14
CN1520299A (zh) 2004-08-11
CA2447598A1 (en) 2002-11-28
HUP0400988A3 (en) 2006-07-28
WO2002094176A2 (en) 2002-11-28
JP2004536063A (ja) 2004-12-02
BR0209855A (pt) 2004-06-15
WO2002094176A3 (en) 2003-12-11
PL367093A1 (en) 2005-02-21

Similar Documents

Publication Publication Date Title
SK14102003A3 (sk) Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv
US7312321B2 (en) Antibody to human enzymes of the metalloprotease family
S Anthony et al. Structure based drug design of angiotensin-I converting enzyme inhibitors
Fukami et al. Chymase: its pathophysiological roles and inhibitors
KR101284884B1 (ko) 정상의 세포보호 활성 및 저하된 항응고 활성을 지닌활성화 단백질 c 변이체
JP2004533209A (ja) ブルトンチロシンキナーゼおよびブルトンチロシンキナーゼ媒体のモデュレーターおよびその同定方法および骨粗鬆症および関連疾患状態の治療および予防におけるその使用
JP2002541776A (ja) ヒトphexの可溶性形態の組成物、方法及び合成試薬
KR20010041418A (ko) 프로테아제-활성화되는 수용체 4 및 그것의 사용
US8389284B2 (en) Screening and treatment methods using IGS5 enzymes of the metalloprotease family
MXPA03011331A (es) Tratamiento del dolor mediante el direccionamiento de canales se abren por un nucleotido ciclico, activado mediante hiperpolarizacion.
Sun et al. Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-terminal part of species-specific amyloid-β peptides
WO1998033812A1 (en) Mast cell protease peptide inhibitors
Brandt et al. Search for substrates for prolyl oligopeptidase in porcine brain
KR20160086775A (ko) Pin1 저해제를 유효성분으로 포함하는 뇌졸중 예방 또는 치료용 약학적 조성물
AU2003282660A1 (en) Vasoregulating compounds and methods of their use
Robl et al. Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin-converting enzyme
KR20030094417A (ko) 의약제조에 있어서 결합된 nep/mp 저해 활성을 가진화합물의 사용
AU2002338919A1 (en) Use of compounds with combined NEP/MP-inhibitory activity in the preparation of medicaments
JP2003012541A (ja) 血管新生阻害剤
WO2011109874A1 (en) Inhibition of glutathione transferase zeta
David-Basei et al. Aminopeptidase A inhibitors
JP2002517239A (ja) ベータセクレターゼ型活性をもつポリペプチド